BIO
Bio-Rad Laboratories, Inc.Class A
Latest price
As of Oct 26, 2026, 6:30 PM EDT · Market data by Massive
Market cap
$9.9B
Volume
179.1K
Previous close
$369.95
Day range
$369.76 – $376.00
Listed
Feb 29, 1980
Coverage
11 articles
Price performance
Recent trading
Newsroom
Latest BIO coverage
Announcement of B-BIO's Own Ecosystem of Projects Under B-BIO, Formation of a Consortium With the BITONE Foundation, and Participation in the Bioland Project
[ad_1] Seoul, Korea – (NewMediaWire) – February 26, 2023 – BAB Foundation, a project under B-BIO, a healthcare device company, announces the launch of its own ecosystem based on patient-generated health data (PGHD). Patients who need periodic blood component analysis, such as diabetes, will be equipped with B-BIO's Bluetooth
Biome Announces OTCQB Listing | Investing News Network
[ad_1] Biome Grow Inc. (CSE:BIO) is happy to announce that it'll begin buying and selling on the OTCQB® from January 2, 2019. OTC Markets Group has additionally accredited Biome’s stock to commerce underneath the brand new stock image BIOIF. Biome Grow Inc. (CSE:BIO) is happy to announce that it'll begin buying and selling on the ...
The Right Way to Address Prescription Drug Costs
[ad_1] Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to define for policymakers the very best strategy for tackling the affordability of pharmaceuticals. “As policy professionals from different sides of the aisle, we believe there is a right way to address these issues and a ...
BIO Illustrates the Success of the Orphan Drug Act
[ad_1] The numbers may shock you. Approximately 7,000 uncommon ailments are identified to exist, and roughly 30 new ones are recognized every year. Also generally known as orphan ailments, they're outlined as these which have an effect on fewer than 200,000 sufferers in America. And whereas it may be true that every uncommon illness solely ...
Road to 2018 Farm Bill Was Years in the Making
[ad_1] Contrary to some beliefs, the Farm Bill helps extra than simply America’s agriculture sector. The invoice’s power title packages present important help to corporations and producers engaged on improvements in renewable chemical compounds, superior biofuels and different merchandise of business biotechnology all through the worth chain. And these appli
From Disease to Looming Food Crisis, Gene Editing Could Unlock Solutions to Our Greatest Problems
[ad_1] Today, celiac illness impacts one in 100 folks worldwide, and with no remedy, the one therapy is a gluten-free weight-reduction plan. However, scientists at the moment are exploring how gene modifying expertise, like CRISPR, may modify the protein of wheat in order that these with celiac illness may get pleasure from meals that sometimes ...
BIO Supports Renegotiated U.S. Japan Trade Agreement
[ad_1] BIO helps the U.S. Trade Representative’s (USTR) negotiations with the Government of Japan as a possibility to develop U.S. exports and create U.S. jobs. We would strongly urge the U.S. authorities to construct on the latest U.S.-Mexico-Canada settlement and that the settlement comprehensively addresses the biotechnology sector as an engine for progre
Interactive Map Displays Strength of Industry’s National Footprint
[ad_1] BIO’s biennial financial growth and jobs report focuses on the financial progress and nationwide footprint of the bioscience business. As the business’s go-to useful resource for efficiency, positioning and traits, this necessary reference device for advocacy and messaging demonstrates the worth of the business’s constant file of producing high-qualit
BIO Hosts Embassy Briefing on International Economic Development
[ad_1] Last week BIO hosted embassy representatives from over 25 international locations to debut a brand new report that highlights methods, insurance policies and finest practices which have been profitable in creating an surroundings during which biotechnology innovation can flourish all over the world. The fifth version of the Building the Bioeconomy rep
The Administration’s Orwellian Defense of Importing Foreign Price Controls
[ad_1] The Trump administration is out with a new blog post defending its plan to undertake international value controls for medicines coated underneath Medicare Part B. The weblog was written within the wake of growing backlash from free-market thought leaders who're difficult the administration’s draconian proposal. The newest weblog put up from the Depart
Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio
[ad_1] During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a dialogue about innovation happening in the biopharma business, the price and worth of prescription medicines and how the latest midterm elections might influence the drug pricing debate. “The latest indications are that for every $1 we ...